Overview

The SPECTRA Study

Status:
Terminated

Trial end date:
2003-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare IL-1ra and the combination of IL-1ra and PEGsTNF-RI with respect to their ability to reduce inflammation and bone and cartilage destruction in the synovium of subjects with rheumatoid arthritis.

Phase:

Phase 2

Details

Lead Sponsor:

Amgen

Treatments:

Interleukin 1 Receptor Antagonist Protein